Panos Kanavos

Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending

Olivier J. Wouters, Panos Kanavos, Martin McKee · Milbank Quarterly · 2017 · 283 citations · Full text

Assessing the economic challenges posed by orphan drugs

Michael Drummond, David A. Wilson, Panos Kanavos et al. · International Journal of Technology Assessment in Health Care · 2007 · 265 citations

Drug Policy, Policy Analysis, Harm Reduction +18

Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework

Aris Angelis, Panos Kanavos · Social Science & Medicine · 2017 · 200 citations · Full text

Clinical Decision-making, Advance Value Framework, Value Theory +19

Encouraging the use of generic medicines: implications for transition economies.

Derek King, Panos Kanavos · PubMed · 2002 · 190 citations

Economics, Generic Drugs, Key Role +13

Centralized Drug Review Processes In Australia, Canada, New Zealand, And The United Kingdom

Steven G. Morgan, Meghan McMahon, Craig Mitton et al. · Health Affairs · 2006 · 186 citations

Drug Policy, Evidence-based Medicine, Health Politics +21